Lataste X, Emre M, Davis C, Groves L
CNS Department, Clinical Research & Development, Sandoz Pharma Ltd, Basel, Switzerland.
Neurology. 1994 Nov;44(11 Suppl 9):S53-9.
The therapeutic profile of a new antispastic drug cannot be defined solely on the basis of placebo-controlled studies. Its potential advantages must be evaluated in comparison with existing drugs. This review compares the efficacy and tolerability of tizanidine, a newer muscle relaxant, with that of baclofen and diazepam, the most widely used antispastic agents, for a variety of diagnoses and target symptoms associated with spasticity. More than 20 double-blind, comparative studies were conducted between 1977 and 1987. These included a total of 777 patients suffering from spasticity of various causes. The collected clinical data have been integrated into a combined analysis. Tizanidine emerges from this comparison as a valuable drug in the treatment of spasticity related to cerebral and spinal disorders.
一种新型抗痉挛药物的治疗概况不能仅基于安慰剂对照研究来确定。必须与现有药物相比较来评估其潜在优势。本综述比较了新型肌肉松弛剂替扎尼定与最广泛使用的抗痉挛药物巴氯芬和地西泮在各种与痉挛相关的诊断和目标症状方面的疗效和耐受性。1977年至1987年间进行了20多项双盲对比研究。这些研究总共纳入了777例患有各种原因导致的痉挛的患者。收集到的临床数据已整合到一项综合分析中。通过此次比较，替扎尼定成为治疗与脑和脊髓疾病相关痉挛的一种有价值的药物。
